Transgenomic Inc (TBIO) 4.2300 $TBIO
Transgenomic Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:05PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the first quarter ended March 31, 2014, and provided a business update.
Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
Business Wire - Wed May 07, 8:36AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces Uplisting to the NASDAQ Capital Market
Business Wire - Tue May 06, 6:01AM CDT
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Friday, May 9, 2014, the stock will trade on NASDAQ under the symbol TBIO.
Transgenomic to Hold First Quarter Financial Results Conference Call on May 7, 2014
Business Wire - Wed Apr 30, 8:37AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:
Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services
Business Wire - Fri Apr 04, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
Dr. Michael A. Luther Joins Transgenomic's Board of Directors
Business Wire - Wed Mar 19, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced the appointment of Michael A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. His appointment became effective March 13, 2014.
Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Business Wire - Wed Mar 12, 3:10PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2013, and provided a business update.
Reminder: Transgenomic to Hold Fourth Quarter Financial Results Conference Call Today
Business Wire - Wed Mar 12, 7:44AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"
, a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million.
Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
Transgenomic Announces Issuance of Key U.S. Patent for ICE COLD-PCR
Business Wire - Tue Jan 21, 6:00AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent related to its licensed ICE COLD-PCR technology. The patent, titled "Full cold-PCR enrichment with reference blocking sequence", was assigned U.S. Patent No. 8,623,603 and is set to expire in 2031.
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests
Business Wire - Thu Jan 16, 6:19AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon's Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.
Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio
Business Wire - Thu Jan 16, 6:00AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has filed an application for listing its common shares on The NASDAQ Capital Market.
2013 Report on the International Molecular Diagnostics Markets
M2 - Mon Jan 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/82rrrq/molecular) has announced the addition of the "Molecular Diagnostics Markets" report to their offering. This report helps readers by Identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing. Readers will also obtain a complete understanding of the chief molecular diagnostics tests--i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; The research will help people discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; By focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts, readers will gain a thorough understanding of the molecular diagnostic market. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics and PCR Technology 3. Business Landscape for the Molecular Diagnostics Market Sectors 4. Overview of Clinical Molecular Diagnostic Platforms on the Market 5. Molecular Diagnostic Testing and Infectious Diseases 6. Cancer Detection Using Molecular Diagnostics 7. Genetics Testing in Molecular Diagnostics 8. Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics 9. Bioterrorism and Molecular Diagnostics 10. Regulatory Requirements 11. Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing 12. Company Profiles Companies Mentioned: - Abbott Laboratories - Beckman Coulter - Cancer Genetics, Inc - DiagnoCure, Inc - Exiqon - Genera Biosystems - Hologic - Illumina - Luminex - Myriad Genetics, Inc - Nanosphere - Orion Genomics - PerkinElmer Genetics - Progenika - QIAGEN NV - Roche Diagnostics - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - Siemens Healthcare Diagnostics (Siemens) - Spartan Bioscience - Thorne Diagnostics - Transgenomic - TrimGen - Trovagene, Inc - Veredus Laboratories - Veridex For more information visit http://www.researchandmarkets.com/research/82rrrq/molecular
Faruqi & Faruqi, LLP Launches An Investigation Against Transgenomic Inc. (TBIO) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Transgenomic Inc. ("Transgenomic" or the "Company" (OTC: TBIO) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for amendments to the Company's 2006 Equity Incentive Plan
Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit
Business Wire - Mon Nov 18, 6:30AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Stephen R. Miller has been named Senior Vice President and General Manager, Patient Testing.
Transgenomic Down 18.5%, Shares Slide into the Red (TBIO)
Comtex SmarTrend(R) - Fri Nov 08, 11:44AM CST
Transgenomic (NASDAQ:TBIO) is one of today's worst performing penny stocks, down 18.5% to $0.44 on 1.3x average daily volume. Thus far today, Transgenomic has traded 324,000 shares, vs. average volume of 255,000 shares per day. The stock has underperformed the Dow (-20.0% to the Dow's 0.6%) and underperformed the S&P 500 (-20.0% to the S&P's 0.9%) during today's trading.
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DGX' New Genetic Test for Opioid Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 9:30AM CDT
Recently, Quest Diagnostics introduced its latest lab-developed genetic test for the delivery of personalized opioid pain-relieving treatment.
Transgenomic Reports First Quarter 2014 Financial Results
Business Wire - Wed May 07, 3:05PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the first quarter ended March 31, 2014, and provided a business update.
Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
Business Wire - Wed May 07, 8:36AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces Uplisting to the NASDAQ Capital Market
Business Wire - Tue May 06, 6:01AM CDT
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Friday, May 9, 2014, the stock will trade on NASDAQ under the symbol TBIO.
Transgenomic to Hold First Quarter Financial Results Conference Call on May 7, 2014
Business Wire - Wed Apr 30, 8:37AM CDT
Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:
Transgenomic Announces Collaboration with Raptor Pharmaceuticals for Genetic Testing Services
Business Wire - Fri Apr 04, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. (NASDAQ: RTPT) to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.
Dr. Michael A. Luther Joins Transgenomic's Board of Directors
Business Wire - Wed Mar 19, 6:00AM CDT
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced the appointment of Michael A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also become a member of the Board's audit committee. His appointment became effective March 13, 2014.
Transgenomic Reports Fourth Quarter and Fiscal Year 2013 Financial Results
Business Wire - Wed Mar 12, 3:10PM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today reported financial results for the fourth quarter and year ended December 31, 2013, and provided a business update.
Reminder: Transgenomic to Hold Fourth Quarter Financial Results Conference Call Today
Business Wire - Wed Mar 12, 7:44AM CDT
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 12, 2014
Business Wire - Thu Mar 06, 10:51AM CST
Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic Announces $7 Million Convertible Preferred Stock Financing
Business Wire - Thu Mar 06, 6:30AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has entered into an agreement with affiliates of Third Security, LLC ("Third Security"
, a leading life sciences investment firm founded by R.J. Kirk, to sell to them 1,443,297 million Series B convertible preferred shares at a price of $4.85 per share for gross proceeds of $7.0 million. Barrick Announces Agreement to Divest its Minority Interest in Marigold in Nevada
Marketwire - Tue Feb 04, 12:11AM CST
All amounts expressed in US dollars unless otherwise indicated.
Transgenomic Announces Issuance of Key U.S. Patent for ICE COLD-PCR
Business Wire - Tue Jan 21, 6:00AM CST
Transgenomic, Inc. (OTCBB:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent related to its licensed ICE COLD-PCR technology. The patent, titled "Full cold-PCR enrichment with reference blocking sequence", was assigned U.S. Patent No. 8,623,603 and is set to expire in 2031.
Horizon Discovery and Transgenomic Announce Collaboration for Validation Control and Development of Genetic Diagnostic Tests
Business Wire - Thu Jan 16, 6:19AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls. The collaboration will enable Transgenomic to transition from the use of plasmid-derived controls, to Horizon's Quantitative Molecular Reference Standards for all of its existing assays, and for any new assays developed in future.
Transgenomic Files Application for The NASDAQ Capital Market Listing and Board Approves Reverse Stock Split Ratio
Business Wire - Thu Jan 16, 6:00AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that it has filed an application for listing its common shares on The NASDAQ Capital Market.
2013 Report on the International Molecular Diagnostics Markets
M2 - Mon Jan 13, 6:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/82rrrq/molecular) has announced the addition of the "Molecular Diagnostics Markets" report to their offering. This report helps readers by Identifying viable technology drivers through a comprehensive look at platform technologies for molecular diagnostics, including probe-based nucleic acid assays, microarrays and sequencing. Readers will also obtain a complete understanding of the chief molecular diagnostics tests--i.e., predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic--from their basic principles to their applications; The research will help people discovering feasible market opportunities by identifying high-growth applications in different clinical diagnostic areas and by focusing on expanding markets, such as communicable diseases, cardiology and oncology; By focusing on global industry development through an in-depth analysis of the major world markets for molecular diagnostics, including growth forecasts, readers will gain a thorough understanding of the molecular diagnostic market. Key Topics Covered: 1. Overview 2. Introduction to Molecular Diagnostics and PCR Technology 3. Business Landscape for the Molecular Diagnostics Market Sectors 4. Overview of Clinical Molecular Diagnostic Platforms on the Market 5. Molecular Diagnostic Testing and Infectious Diseases 6. Cancer Detection Using Molecular Diagnostics 7. Genetics Testing in Molecular Diagnostics 8. Molecular Diagnostics Uses in Industrial Testing and Food Diagnostics 9. Bioterrorism and Molecular Diagnostics 10. Regulatory Requirements 11. Reimbursement Issues and Billing Landscape for Molecular Diagnostics Testing 12. Company Profiles Companies Mentioned: - Abbott Laboratories - Beckman Coulter - Cancer Genetics, Inc - DiagnoCure, Inc - Exiqon - Genera Biosystems - Hologic - Illumina - Luminex - Myriad Genetics, Inc - Nanosphere - Orion Genomics - PerkinElmer Genetics - Progenika - QIAGEN NV - Roche Diagnostics - Rosetta Genomics Ltd - Seegene - Sequenom, Inc - Siemens Healthcare Diagnostics (Siemens) - Spartan Bioscience - Thorne Diagnostics - Transgenomic - TrimGen - Trovagene, Inc - Veredus Laboratories - Veridex For more information visit http://www.researchandmarkets.com/research/82rrrq/molecular
Faruqi & Faruqi, LLP Launches An Investigation Against Transgenomic Inc. (TBIO) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Business Wire - Fri Dec 27, 1:42PM CST
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Transgenomic Inc. ("Transgenomic" or the "Company"
(OTC: TBIO) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for amendments to the Company's 2006 Equity Incentive Plan Transgenomic Appoints Stephen R. Miller as Senior Vice President and General Manager of Patient Testing Business Unit
Business Wire - Mon Nov 18, 6:30AM CST
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced that Stephen R. Miller has been named Senior Vice President and General Manager, Patient Testing.
Transgenomic Down 18.5%, Shares Slide into the Red (TBIO)
Comtex SmarTrend(R) - Fri Nov 08, 11:44AM CST
Transgenomic (NASDAQ:TBIO) is one of today's worst performing penny stocks, down 18.5% to $0.44 on 1.3x average daily volume. Thus far today, Transgenomic has traded 324,000 shares, vs. average volume of 255,000 shares per day. The stock has underperformed the Dow (-20.0% to the Dow's 0.6%) and underperformed the S&P 500 (-20.0% to the S&P's 0.9%) during today's trading.
OTC Daily Alert Stock Watch - Transgenomic, Inc. (OTCQB: TBIO)
WorldStockWire - Thu Sep 05, 4:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
DGX' New Genetic Test for Opioid Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 9:30AM CDT
Recently, Quest Diagnostics introduced its latest lab-developed genetic test for the delivery of personalized opioid pain-relieving treatment.
